Efficacy and safety of pregabalin in refractory focal epilepsy with and without comorbid anxiety disorders - Results of an open-label, parallel group, investigator-initiated, proof-of-concept study

Epilepsy and Behavior

Volumn 29, Issue 2, 2013, Pages 298-304

  Brandt, Christian ^a,b   Schoendienst, Martin ^a   Trentowska, Monika ^c   Schrecke, Mario ^a   Fueratsch, Nora ^d   Witte Boelt, Karin ^b   Pohlmann Eden, Bernd ^e   May, Theodor W ^b  

^a EPILEPSY CENTER BETHEL   (Germany)

^b Society for Epilepsy Research   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d Epilepsy Centre Berlin Brandenburg   (Germany)

^e DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Anxiety; Epilepsy; Pregabalin; Psychiatric comorbidity; Treatment

Indexed keywords

CARBAMAZEPINE; CITALOPRAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OLANZAPINE; OPIPRAMOL; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; QUETIAPINE; TOPIRAMATE; VALPROIC ACID;

ADJUSTMENT DISORDER; ADULT; AGORAPHOBIA; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ANXIETY DISORDER; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DYSTHYMIA; EATING DISORDER; ELECTROOCULOGRAM; EVOKED RESPONSE AUDIOMETRY; FEMALE; FOCAL EPILEPSY; GENERALIZED ANXIETY DISORDER; HUMAN; LIFE SATISFACTION; MAJOR DEPRESSION; MALE; MOOD DISORDER; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; OUTCOME ASSESSMENT; PANIC; PARALLEL DESIGN; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; SIMPLE PARTIAL SEIZURE; SOCIAL INTERACTION ANXIETY SCALE; SOCIAL PHOBIA; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SYMPTOM CHECKLIST 90; TREATMENT DURATION;

ANXIETY; EPILEPSY; PREGABALIN; PSYCHIATRIC COMORBIDITY; TREATMENT;

ACTIVITIES OF DAILY LIVING; ADULT; ANALYSIS OF VARIANCE; ANTICONVULSANTS; ANXIETY DISORDERS; COMORBIDITY; ELECTROENCEPHALOGRAPHY; EPILEPSIES, PARTIAL; FEMALE; FOLLOW-UP STUDIES; GAMMA-AMINOBUTYRIC ACID; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84885066552     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2013.08.004     Document Type: Article

References (41)

1. Kanner A.M. Psychiatric issues in epilepsy: the complex relation of mood, anxiety disorders and epilepsy. Epilepsy Behav 2009, 15:83-87.
2. Jones J.E., Bell B., Fine J., Rutecki P., Seidenberg M., Hermann B. A controlled prospective investigation of psychiatric comorbidity in temporal lobe epilepsy. Epilepsia 2007, 48(12):2357-2360.
3. Gaitatzis A., Trimble M.R., Sander J.W. The psychiatric comorbidity of epilepsy. Acta Neurol Scand 2004, 110(4):207-220.
4. Gaitatzis A., Carroll K., Majeed A., Sander J.W.A.S. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 2004, 45(12):1613-1622.
5. Gilliam F., Hecimovic H., Sheline Y. Psychiatric comorbidity, health, and function in epilepsy. Epilepsy Behav 2003, 4(Suppl. 4):S26-S30.
6. Kanner A.M., Barry J.J., Gilliam F., Hermann B., Meador K.J. Anxiety disorders, subsyndromic depressive episodes, and major depressive episodes: do they differ on their impact on the quality of life of patients with epilepsy?. Epilepsia 2010, 51(7):1152-1158.
7. Brandt C., Schoendienst M., Trentowska M., May T.W., Pohlmann-Eden B., Tuschen-Caffier B., et al. Prevalence of anxiety disorders in patients with refractory focal epilepsy-a prospective clinic based survey. Epilepsy Behav 2010, 17(2):259-263.
8. French J.A., Kugler A.R., Robbins J.L., Knapp L.E., Garofalo E.A. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003, 60(10):1631-1637.
9. Arroyo S., Anhut H., Kugler A.R., Lee C.M., Knapp L.E., Garofalo E.A., et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004, 45(1):20-27.
10. Beydoun A., Uthman B.M., Kugler A.R., Greiner M.J., Knapp L.E., Garofalo E.A. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005, 64(3):475-480.
11. Elger C.E., Brodie M.J., Anhut H., Lee C.M., Barrett J.A. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 2005, 46(12):1926-1936.
12. Feltner D., Wittchen H.U., Kavoussi R., Brock J., Baldinetti F., Pande A.C. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008, 23(1):18-28.
13. Montgomery S., Chatamra K., Pauer L., Whalen E., Baldinetti F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry 2008, 193(5):389-394.
14. Montgomery S.A., Tobias K., Zornberg G.L., Kasper S., Pande A.C. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006, 67(5):771-782.
15. Rickels K., Pollack M.H., Feltner D.E., Lydiard R.B., Zimbroff D.L., Bielski R.J., et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005, 62(9):1022-1030.
16. Feltner D.E., Crockatt J.G., Dubovsky S.J., Cohn C.K., Shrivastava R.K., Targum S.D., et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003, 23(3):240-249.
17. Pande A.C., Crockatt J.G., Feltner D.E., Janney C.A., Smith W.T., Weisler R., et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003, 160(3):533-540.
18. Pande A.C., Feltner D.E., Jefferson J.W., Davidson J.R., Pollack M., Stein M.B., et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004, 24(2):141-149.
19. Wittchen H.-U., Wunderlich U., Gruschwitz S., Zaudig M. SKID I. Strukturiertes Klinisches Interview fur DSM-IV. Achse I: Psychische Storungen 1997, Hogrefe, Goettingen.
20. Schoendienst M., Reuber M. Epilepsy and anxiety. Behavioral aspects of epilepsy 2008, 219-226. Demos, New York. S. Schachter, G. Holmes, D. Kasteleijn-Nolst Trenité (Eds.).
21. Chambless D.L., Caputo G.C., Bright P., Gallagher R. Assessment of fear of fear in agoraphobics: the Body Sensations Questionnaire and the Agoraphobic Cognitions Questionnaire. J Consult Clin Psychol 1984, 52:1090-1097.
22. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
23. Fahrenberg J., Myrtek M., Schumacher J., Brähler E. Fragebogen zur Lebenszufriedenheit (FLZ). Handanweisung 2000, Hogrefe, Göttingen.
24. May T.W., Pfaefflin M. Evaluating comprehensive care: description of the PESOS and its psychometric properties. Comprehensive care for people with epilepsy 2001, 319-340. John Libbey & Company Ltd, Eastleigh. M. Pfaefflin, R.T. Fraser, R. Thorbecke, U. Specht, P. Wolf (Eds.).
25. Derogatis L.R. SCL-90-R, administration, scoring and procedures manual-I for the revised version 1977, Johns Hopkins University School of Medicine, Baltimore.
26. Heimberg R., Mueller G., Holt C., Hope D., Liebowitz M. Assessment of anxiety in social interaction and being observed by others: the Social Interaction Anxiety Scale and the Social Phobia Scale. Behav Ther 1992, 23:53-73.
27. Spielberger C.D., Gorssuch R.L., Lushene P.R., Vagg P.R., Jacobs G.A. Manual for the State-Trait Anxiety Inventory 1983, Consulting Psychologists Press, Palo Alto, CA.
28. Glöckner-Rist A., Stieglitz R.-D. TBS-TK Rezension: "SCL-90-R - Die Symptom-Checkliste von L. R. Derogatis (Deutsche version)". Psychol Rundsch 2011, 63:73-75.
29. Kammer D. Study of the psychometric properties of the German Beck Depression Inventory (BDI). Diagnostica 1983, 29(1):48-60.
30. Laux L., Glanzmann P., Schaffner P., Spielberger C.D. Das State-Trait-Angstinventar 1981, Beltz, Weinheim.
31. Ehlers A., Margraf J., Chambless D.L. Fragebogen zu körperbezogenen Ängsten, Kognitionen und Vermeidung, AKV 1993, Beltz-Test, Weinheim.
32. Rabung S., Jaeger U., Streeck U., Leichsenring F. Psychometrische Überprüfung der Social Phobia Scale (SPS) und der Social Interaction Anxiety Scale (SIAS) im statonären Setting. Diagnostica 2006, 52(3):143-153.
33. Fahrenberg J., Myrtek M., Schumacher J., Brähler E. Fragebogen zur Lebenszufriedenheit (FLZ) 2000, Hogrefe, Göttingen.
34. Brandt C., May T.W., Pohlmann-Eden B., Nieder E., Elsner H., Witte-Boelt K., et al. Retention rate of pregabalin in drug-resistant epilepsy: 1-year follow-up, single-centre observation in 105 consecutive, adult patients. Seizure 2009, 18(9):634-638.
35. Kanner A.M. Psychiatric issues in epilepsy: the complex relation of mood, anxiety disorders, and epilepsy. Epilepsy Behav 2009, 15(1):83-87.
36. Jones N.C., Salzberg M.R., Kumar G., Couper A., Morris M.J., O'Brien T.J. Elevated anxiety and depressive-like behavior in a rat model of genetic generalized epilepsy suggesting common causation. Exp Neurol 2008, 209(1):254-260.
37. Mula M., Pini S., Cassano G.B. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007, 27(3):263-272.
38. Blocher J.B., Fujikawa M., Sung C., Jackson D.C., Jones J.E. Computer-assisted cognitive behavioral therapy for children with epilepsy and anxiety: a pilot study. Epilepsy Behav 2013, 27(1):70-76.
39. Macrodimitris S., Wershler J., Hatfield M., Hamilton K., Backs-Dermott B., Mothersill K., et al. Group cognitive-behavioral therapy for patients with epilepsy and comorbid depression and anxiety. Epilepsy Behav 2011, 20(1):83-88.
40. Faught E., Ayala R., Montouris G.G., Leppik I.E. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001, 57(10):1774-1779. Zonisamide 922 Trial G.
41. Hagemann A., May T.W., Nieder E., Witte-Bolt K., Pohlmann-Eden B., Elger C.E., et al. Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy. Epilepsy Res 2013, 104(1-2):140-150.